Daisy Zhao joined POL Scientific in 2025. She added to the team a wealth of experience accumulated over four years in the publishing industry. Now she is responsible for overseeing operations and journal management. This dedication to advancing scholarly communication aligns seamlessly with the mission of POL Scientific, and the strategic vision brought to the organization is expected to drive continued growth and achievement

 

Academician-Chinese Academy of Science

Prof. Xu Zhang is the director and professor of urology at the Chinese PLA General Hospital in Beijing, China. He is the Chairman designate of Chinese Urological Association. He has long committed to promote the development of minimally invasive urology in China. He has personally performed over 10,000 cases of laparoscopic procedures and over 5000 cases of robotic procedures, established and promoted retroperitoneal laparoscopic surgeries, and pioneered in many new techniques of robotic procedures such as robotic IVC thrombectomy, robotic kidney transplantation, robotic prostatectomy and robotic partial nephrectomy. He had been invited to perform live surgery at many international conferences for the last 20 consecutive years and trained more than 1300 urological laparoscopic specialists at home and abroad.

 

Academician - Chinese Academy of Sciences

Prof. Shang is the Professor of Biochemistry and Molecular Biology at Peking University Health Science Center, China. He is an accomplished Molecular Biologist whose research focuses on the molecular mechanisms driving breast and endometrial cancers. He obtained his Ph.D. from Pennsylvania State University and conducted postdoctoral research in the laboratory of Dr. Myles Brown at the Dana-Farber Cancer Institute, Harvard Medical School. In 2002, he returned to China to establish his research program at Peking University. Dr. Shang's work has led to significant insights into estrogen signaling, epigenetic regulation in metastasis, and novel tumorigenesis genes, published in leading international journals. His scientific excellence was recognized with his election as an Academician of the Chinese Academy of Sciences in 2009. Complementing his research, Dr. Shang has served in key leadership roles, including as President of Tianjin Medical University and Capital Medical University, and contributes to the scientific community through editorial board service.

 

National Center for Nanoscience and Technology, Beijing, China

Dr. Xingjie Liang earned his Ph.D. from the National Key Laboratory of Biomacromolecules at the Institute of Biophysics, Chinese Academy of Sciences (CAS). He subsequently completed five years of postdoctoral training in the laboratory of Dr. Michael M. Gottesman at the National Cancer Institute, NIH, followed by a Research Fellow position at the Surgical Neurology Branch, NINDS, NIH. He is currently a Principal Investigator at the Center for Excellence in Nanoscience, CAS. Dr. Liang serves as the President of the Chinese Association of Nanobiology and is an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He has led the development of an "Injectable Nanomicelle Powder with Irinotecan," which has received CFDA approval and advanced to clinical trials. His research focuses on leveraging nanotechnology to enhance drug bioavailability and therapeutic efficacy against cancers and infectious diseases, with a current program aimed at overcoming clinical adaptive treatment tolerance.

 

The University of Kansas Medical Center

Professor Benyi Li received his medical training in China and completed his Ph.D. work in Japan. He moved to the United States in 1998 and transitioned to urological research. After completing two postdoctoral fellowships at Moffitt Cancer Center and Baylor College of Medicine, he joined the faculty of the University of Kansas Medical Center's Urology department at the end of 2001 and established the department's basic research program. His research focuses on prostate cancer, with a focus on developing innovative clinical therapies for patients with advanced prostate cancer. His laboratory is dedicated to uncovering the molecular mechanisms of cancer development and developing novel therapeutic strategies based on these insights.

 

David Wang joined POL Scientific in August 2025. He has been a journal editor for eight years within the publishing industry before joining POL Scientific Publishing. Now he is responsible to develop and maintain the journal’s publishing ethics policies, which are set in line with COPE, ICMJE and DOAJ guidelines. His commitment to the highest standards of quality and integrity remains unshakable.

 

Eleanore Yang, who holds a master's degree in Environmental Engineering, joined POL Scientific as Production Manager in 2025. With eight years of extensive experience in the publishing industry, she oversees the entire article production process, from acceptance to online release.